Walleye Capital LLC Akero Therapeutics, Inc. Transaction History

Walleye Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$18.31 - $24.62 $231,200 - $310,876	12,627 Added 113.96%	23,707 $556,000
Q1 2024 May 15, 2024	SELL	$17.76 - $31.18 $2.11 Million - $3.71 Million	-118,937 Reduced 91.48%	11,080 $279,000
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $1.48 Million - $6.54 Million	130,017 New	130,017 $3.04 Million
Q2 2023 Aug 14, 2023	SELL	$36.89 - $56.88 $1.69 Million - $2.6 Million	-45,755 Reduced 43.4%	59,677 $2.79 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $591,251 - $797,007	15,864 Added 17.71%	105,432 $4.03 Million
Q4 2022 Feb 14, 2023	SELL	$33.44 - $54.8 $3.83 Million - $6.27 Million	-114,475 Reduced 56.1%	89,568 $4.91 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $2.07 Million - $6.95 Million	204,043 New	204,043 $6.95 Million

191

74.6M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.39B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.